Bristol-Myers Squibb to present cancer drug data at ASCO 2015

Bristol-Myers Squibb has announced that it will be attending the upcoming annual meeting of the American Society of Clinical Oncology (ASCO), where it will be presenting new clinical research on three of its immuno-oncology agents.

The conference in Chicago from May 29th to June 2nd will give the company the opportunity to present data for Opdivo and Yervoy across multiple solid tumour types, as well as elotuzumab in relapsed or refractory multiple myeloma.

Phase III study data will demonstrate Opdivo's efficacy in the treatment of non-small cell lung cancer and the benefits of an Opdivo/Yervoy combination therapy for advanced melanoma.

These two therapies have also demonstrated efficacy against renal cell carcinoma, hepatocellular carcinoma and glioblastoma.

Francis Cuss, executive vice-president and chief scientific officer at Bristol-Myers Squibb, said: "Patients are the inspiration behind our pioneering research in the field of immuno-oncology, which has led to the approval of novel agents for the treatment of some of the hardest to treat cancers."

Opdivo was recommended for EU approval by the Committee for Medicinal Products for Human Use for the treatment of advanced melanoma last month.